SCHEMBL4886418

SCHEMBL4886418

NS(=O)(=O)c1ccc(CNC(=S)NCCc2ccccc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 14/20 0.72
CA2 P00918 14/20 0.72
CA12 O43570 10/20 0.72
CA9 Q16790 9/20 0.72
ALDH1A1 P00352 5/20 0.72
TAAR1 Q96RJ0 2/20 0.72
LMNA P02545 1/20 0.72
THRB P10828 1/20 0.72
DUSP3 P51452 1/20 0.72
PTPN11 Q06124 1/20 0.72
HPGD P15428 2/20 0.67
CA4 P22748 4/20 0.66
MAPT P10636 1/20 0.65
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
ALOX12 P18054 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
CA5A P35218 3/20 0.64
CA7 P43166 3/20 0.64
CA5B Q9Y2D0 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4888513 0.85 CA2 (0.82) CA1CA2CA12CA9TAAR1
SCHEMBL4890410 0.85 CA1 (0.69) CA1CA2CA12CA9ALDH1A1
SCHEMBL13764561 0.84 CA2 (1.00) CA1CA2CA12CA9ALDH1A1
SCHEMBL11887680 0.81 ALDH1A1 (1.00) CA1CA2CA12CA9ALDH1A1
SCHEMBL6564517 0.80 RAB9A (0.67) CA1CA2CA12CA9ALDH1A1
SCHEMBL15398364 0.80 MEN1 (0.75) ALDH1A1TAAR1LMNAHPGDMAPT
SCHEMBL11887688 0.79 CA2 (1.00) CA1CA2CA12CA9ALDH1A1
SCHEMBL6646140 0.79 ALDH1A1 (0.69) CA1CA2CA12CA9ALDH1A1
SCHEMBL13401863 0.78 CA2 (0.74) CA1CA2CA12CA9ALDH1A1
SCHEMBL13401878 0.78 CA1 (0.80) CA1CA2CA12CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071650-B2 Vanilloid receptor modulators; analgesic, antiinflammatory and antiulcer effects; such as 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea PACIFIC CORPORATION (KR) 2011-12-06 US disclosed
US-8071650-B2 Vanilloid receptor modulators; analgesic, antiinflammatory and antiulcer effects; such as 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea PACIFIC CORPORATION (KR) 2011-12-06 US disclosed
US-20080064687-A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same SUH YOUNG G 2008-03-13 US disclosed
US-20080064687-A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same SUH YOUNG G 2008-03-13 US disclosed
EP-1303483-A4 NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME PACIFIC CORP (KR) 2004-11-03 EP disclosed
US-20030153596-A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same PACIFIC CORPORATION (KR) 2003-08-14 US disclosed
EP-1303483-A1 NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME PACIFIC CORPORATION (KR) 2003-04-23 EP disclosed
WO-2002016318-A1 NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME PACIFIC CORPORATION (KR) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153596-A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same TAS2R40, TAS1R2, TAS2R45 CA1 3550/4885CA2 1239/4885CA12 3462/4885
US-20080064687-A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same TRPV1, TRPA1, TAS2R5 CA1 3106/4885CA2 1234/4885CA12 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.